Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 7Lung Neoplasms 7Breast Neoplasms 7Ovarian Neoplasms 5Neoplasm Metastasis 5Endometrial Neoplasms 5Pancreatic Neoplasms 4Fallopian Tube Neoplasms 4Adenocarcinoma Of Esophagus 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Esophageal Neoplasms 3Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Brenner Tumor 2Anatomic Stage I Breast Cancer AJCC v8 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Sinonasal Squamous Cell Carcinoma 1Rectal Neoplasms 1Pancreatic Cystic Neoplasm 1Oropharyngeal Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Metastatic Pancreatic Ductal Adenocarcinoma 1Locally Advanced Cervical Adenocarcinoma 1

Interventions

Oxaliplatin 8Fluorouracil 8Nivolumab 7Leucovorin 7Paclitaxel 6Capecitabine 5Taxes 4Specimen Handling 4pembrolizumab 3Trastuzumab 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Cisplatin 3zimberelimab 2zanidatamab 2Radiotherapy 2Folfox protocol 2Carboplatin 2zolbetuximab 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tislelizumab 1quemliclustat 1obeticholic acid 1futibatinib 1dehydroftorafur 1cixutumumab 1balstilimab 1Saline Solution 1Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Taxes × 30 days × Clear all
NCT01196390 2026-06-02

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
203 enrolled 22 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT01142388 2026-05-29

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled 8 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06203600 2026-05-26

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
224 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Northwestern University

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡